Anika Therapeutics Inc (ANIK) 46.45 $ANIK
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
35.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Fri Jun 27, 9:12AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 35.54% as of today's recent price of $47.00.
Anika Therapeutics Has Returned 31.8% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Thu Jun 19, 4:50PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 31.77% as of today's recent price of $45.69.
Pricing of Offering, FDA Approvals, Launches, and Technical Updates - Analyst Notes on Tenet, Lannett, Wright Medical Group, Anika Therapeutics and Accuray
PR Newswire - Thu Jun 19, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp. (NYSE: THC), Lannett Company, Inc. (NYSE: LCI), Wright Medical Group Inc. (NASDAQ: WMGI), Anika Therapeutics Inc. (NASDAQ: ANIK) and Accuray Incorporated (NASDAQ: ARAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3879-100free.
4 Stocks in Breakout Territory With Big Volume
at The Street - Tue Jun 10, 7:30AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Stocks Hold Modest Gains; Anika Clears Late-Stage Base
at Investor's Business Daily - Mon Jun 09, 12:29PM CDT
Tech stocks were in the driver's seat again Monday as all three major averages kicked off the week on positive ground. The Nasdaq gained 0.5% in early afternoon trade; the S&P 500 added 0.2% and the Dow Jones industrial average rose 0.1%. Volume on...
Shares of ANIK Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 10:15AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 39.81% as of today's recent price of $48.48.
Insider Trading Alert - BHI, REX And ANIK Traded By Insiders
at The Street - Wed Jun 04, 9:08AM CDT
Stocks with insider trader activity include BHI, REX and ANIK
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Stocks Up At Midday; Twitter Climbs On Upgrade
at Investor's Business Daily - Thu May 29, 11:00AM CDT
Stocks were holding on to modest gains at midday Thursday even after revised GDP figures showed that the economy contracted more than expected in the first quarter. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2% to a fresh record high and the Dow...
Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid
Biotech Companies Report Quarterly Financial Results - Analyst Notes on Intrexon, Acorda, Anika, Sangamo and Spectrum
PR Newswire - Wed May 14, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intrexon Corporation (NYSE: XON), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Anika Therapeutics, Inc. (NASDAQ: ANIK), Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2531-100free.
Anika Therapeutics Announces Date of Second-Quarter 2014 Financial Results Conference Call
Business Wire - Tue Jul 15, 3:05PM CDT
Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that it plans to issue its second-quarter 2014 financial results after the close of the market on Wednesday, July 30, 2014. The company plans to hold a conference call the next day, Thursday, July 31 at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.
44.4% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Mon Jul 14, 9:40AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 44.37% as of today's recent price of $50.06.
Biotech Stocks Gilead, Anika Still Near Buy Points
at Investor's Business Daily - Mon Jul 07, 4:39PM CDT
Biotechs Gilead Sciences (GILD) and Anika Therapeutics (ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Anika, which makes treatments for tissue protection, healing and repair, cleared a 49.47 buy...
Uptrend Call Working As Anika Therapeutics Stock Rises 41.6% (ANIK)
Comtex SmarTrend(R) - Mon Jul 07, 9:20AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 5 months, Anika Therapeutics has returned 41.60% as of today's recent price of $49.10.
Appointments, Acquisitions, Study Results, and Technical Updates - Analyst Notes on Alere, AMRI, Anika Therapeutics, Nektar and Sangamo
PR Newswire - Fri Jul 04, 5:30AM CDT
Today, Analysts Review released its analysts' notes regarding Alere Inc. (NYSE: ALR), Albany Molecular Research Inc. (NASDAQ: AMRI), Anika Therapeutics Inc. (NASDAQ: ANIK), Nektar Therapeutics (NASDAQ: NKTR) and Sangamo Biosciences Inc. (NASDAQ: SGMO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4465-100free.
35.5% Return Seen to Date on SmarTrend Anika Therapeutics Call (ANIK)
Comtex SmarTrend(R) - Fri Jun 27, 9:12AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 35.54% as of today's recent price of $47.00.
Anika Therapeutics Has Returned 31.8% Since SmarTrend Recommendation (ANIK)
Comtex SmarTrend(R) - Thu Jun 19, 4:50PM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 4 months, Anika Therapeutics has returned 31.77% as of today's recent price of $45.69.
Pricing of Offering, FDA Approvals, Launches, and Technical Updates - Analyst Notes on Tenet, Lannett, Wright Medical Group, Anika Therapeutics and Accuray
PR Newswire - Thu Jun 19, 5:00AM CDT
Today, Analysts Review released its analysts' notes regarding Tenet Healthcare Corp. (NYSE: THC), Lannett Company, Inc. (NYSE: LCI), Wright Medical Group Inc. (NASDAQ: WMGI), Anika Therapeutics Inc. (NASDAQ: ANIK) and Accuray Incorporated (NASDAQ: ARAY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3879-100free.
4 Stocks in Breakout Territory With Big Volume
at The Street - Tue Jun 10, 7:30AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Stocks Hold Modest Gains; Anika Clears Late-Stage Base
at Investor's Business Daily - Mon Jun 09, 12:29PM CDT
Tech stocks were in the driver's seat again Monday as all three major averages kicked off the week on positive ground. The Nasdaq gained 0.5% in early afternoon trade; the S&P 500 added 0.2% and the Dow Jones industrial average rose 0.1%. Volume on...
Shares of ANIK Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 05, 10:15AM CDT
SmarTrend identified an Uptrend for Anika Therapeutics (NASDAQ:ANIK) on February 21st, 2014 at $34.68. In approximately 3 months, Anika Therapeutics has returned 39.81% as of today's recent price of $48.48.
Insider Trading Alert - BHI, REX And ANIK Traded By Insiders
at The Street - Wed Jun 04, 9:08AM CDT
Stocks with insider trader activity include BHI, REX and ANIK
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Stocks Up At Midday; Twitter Climbs On Upgrade
at Investor's Business Daily - Thu May 29, 11:00AM CDT
Stocks were holding on to modest gains at midday Thursday even after revised GDP figures showed that the economy contracted more than expected in the first quarter. The Nasdaq rose 0.3%, the S&P 500 climbed 0.2% to a fresh record high and the Dow...
Global Hyaluronic Acid Products Market Product Trends and Forecasts, 2019: Single-Injection, Three-Injection Cycle and Five-Injection Cycle Analysis
M2 - Wed May 14, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/snvprr/hyaluronic_acid) has announced the addition of the "Hyaluronic Acid Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Some of the prominent players in the hyaluronic acid products market that have been profiled in this report include Allegran Inc., Anika Therapeutics, Inc., Merz Aesthetics, Inc., Sanofi (Genzyme) and Seikagaku. Hyaluronic acid (HA) is a unique non-sulfated glycosaminoglycan, distributed throughout the body in connective tissues, epithelial and neural tissues. Hyaluronic acid contributes significantly to cell proliferation and migration and is observed to be an integral component of the extracellular matrix. Hyaluronic acid has wide number of applications such as orthopedic surgery, rheumatology, ophthalmology, otolaryngology, dermatology and plastic surgery, wound healing and drug delivery. Hyaluronic acid products are segmented on the basis of treatment regimen into single-injection, three-injection cycle and five-injection cycle products. In addition, HA injectable can be utilized in a range of applications such as osteoarthritis, dermal fillers, ophthalmic surgery and vesicoureteral reflux (VUX). The major factors driving this market are increasing geriatric population globally, high awareness about anti-aging procedures, patient's preference for the treatment with minimum side-effects and rising demand for minimally invasive surgical procedures. In products segment, five-injection cycle products is the largest marketsegment and single-injection market segment is growing with highest CAGR during forecast period from 2013 to 2019. Hyaluronic acid products market is observing a global shift in usage of five-injection cycle to single-injection cycle treatment as there has been a considerable change in preference of patients towards short duration treatment. This shift in preference is mainly related to convenience of patients as they try to avoid side-effects such as redness, inflammation and itching experienced after every treatment and five-injection cycle is a prolonged treatment compared to single-injection. Dermal fillers is the largest market closely followed by osteoarthritis market and vesicoureteral reflux (VUR) applications market. VUR application market for hyaluronic acid products is growing at a highest CAGR during the forecast period from 2013 to 2019. The segment is mainly driven by aging population, high demand for minimally invasive surgical treatments and high awareness about beauty enhancements. Report Scope Hyaluronic Acid Products Market, by Products - Single-injection - Three-injection cycle - Five-injection cycle Hyaluronic Acid Products Market, by Applications - Osteoarthritis - Ophthalmic - Dermal Fillers - Vesicoureteral Reflux (VUR) Hyaluronic Acid Products Market, by Geography - North America - Europe - Asia-Pacific - Rest of the World (RoW) Companies Mentioned - Alcon, Inc. - Allergan, Inc. - Anika Therapeutics, Inc. - F. Hoffmann-La Roche Ltd. - Ferring Pharmaceuticals, Inc. - Fidia Farmaceutici SpA - GALDERMA S.A. - Hyaltech Ltd. - LifeCore Biomedical LLC, - Meiji Seika Pharma Co., Ltd. - Merz Aesthetics, Inc. - Sanofi - Salix Pharmaceuticals, Inc. - Seikagaku Corporation - Shanghai Jingfeng Pharmaceutical Co., Ltd. - Smith & Nephew plc - TRB CHEMEDICA INTERNATIONAL SA - Zimmer Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/sn...ronic_acid
Biotech Companies Report Quarterly Financial Results - Analyst Notes on Intrexon, Acorda, Anika, Sangamo and Spectrum
PR Newswire - Wed May 14, 8:30AM CDT
Today, Analysts Review released its analysts' notes regarding Intrexon Corporation (NYSE: XON), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Anika Therapeutics, Inc. (NASDAQ: ANIK), Sangamo Biosciences, Inc. (NASDAQ: SGMO) and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2531-100free.
